WO2004045595A1 - USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ - Google Patents

USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ Download PDF

Info

Publication number
WO2004045595A1
WO2004045595A1 PCT/EP2003/014864 EP0314864W WO2004045595A1 WO 2004045595 A1 WO2004045595 A1 WO 2004045595A1 EP 0314864 W EP0314864 W EP 0314864W WO 2004045595 A1 WO2004045595 A1 WO 2004045595A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgfβ
pathological conditions
signal
intended
rar
Prior art date
Application number
PCT/EP2003/014864
Other languages
French (fr)
Inventor
André Jomard
Michel Demarchez
Alain Mauviel
Valérie PENDARIES
Franck VERRECCHIA
Serge Michel
Original Assignee
Galderma Research & Development, S.N.C.
MICHEL, Marie-Christine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0214319A external-priority patent/FR2847167A1/en
Application filed by Galderma Research & Development, S.N.C., MICHEL, Marie-Christine filed Critical Galderma Research & Development, S.N.C.
Priority to AU2003302070A priority Critical patent/AU2003302070A1/en
Publication of WO2004045595A1 publication Critical patent/WO2004045595A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Definitions

  • the present invention relates to the use of at least one agent which potentiates the action of TGF ⁇ , for preparing a pharmaceutical composition intended for the treatment or prevention of pathological conditions associated with a deficiency in the TGF ⁇ signal" or requiring an amplification of this signal .
  • TGF ⁇ Transforming Growth Factor- ⁇
  • Smad proteins translate the signal from TGF ⁇ receptors by regulating the transcription of target genes, either directly or in combination with other specific sequence transcription factors.
  • the intracellular signalling cascade for members of the TGF ⁇ superfamily is initiated by binding of the cytokine to a complex of membrane receptors made up of two types of receptor with serine/threonine kinase activity, type I receptors and type II receptors. Binding of the cytokine to the type II receptor induces recruitment and phosphorylation of the type I receptor. Translation of the signal from the membrane to the nucleus then takes place by virtue of a family of proteins, the S ads .
  • the Smad family can be divided up into three subfamilies according to structural and functional criteria.
  • R-Smads (Receptor- regulated Smads), which are specifically activated by the type I receptors, comprise Smadl, Smad5 and Smad8 which are specific for the BMP pathway, and Smad2 and Smad3 which are specific for the TGF ⁇ /activin pathway. Phosphorylation of the R-Smads by the type I receptors takes place on serine residues located at the C-terminal end of the protein (SSXS motif) . Activation of these R-Smads allows the formation of a heterocomplex with another member of the Smad family, common to the various R-Smads, Smad .
  • This protein also referred to as co-Smad (common-partner Smad) , lacks the SSXS sequence and allows the translocation into the nucleus of the R-Smad/Smad4 complex, which can then act as a transcription factor.
  • the third subfamily consists of Smad ⁇ and Smad7, referred to as I-Smads ( Inhibitory-Smads) , which prevent the phosphorylation of R-Smads and thus their association with Smad4 and/or the translocation of the R-Smad/Smad4 complex into the nucleus by interacting directly with Smad4.
  • TGF ⁇ is also involved in other signalling pathways, such as that of MAP/SAP kinase or else the Ras pathway.
  • TGF ⁇ is a key cytokine in the control of connective tissue homeostasis and plays a major role in the profibrotic activity by increasing the expression of connective tissue-specific genes (Mauviel A and Uitto J. (1993) Wounds 5: 137-52).
  • TGF ⁇ plays an important role in immunomodulation processes, by acting on lymphocyte differentiation (Kehrl et al, 1986, J Immunol, 137, 3855-3860, Gorelik and Flavell, 2002, Nature, 2, 46-53).
  • the Applicant has noted, surprisingly, that the use of an RAR receptor antagonist results in potentiation of the action of TGF ⁇ .
  • the present invention proposes a solution for treating pathological conditions associated with a deficiency in the TGF ⁇ signal or requiring an amplification of this signal.
  • retinoids and TGF ⁇ follow complex signalling pathways, which are all the more complex since they differ according to the subtype of receptor activated; by way of example, for retinoids, the signalling pathway depends on the RAR and RXR receptors and on the subtype involved ( ⁇ , ⁇ or ⁇ ) . Finally, it should be noted that these signalling pathways are independent. Thus, the possibility of a retinoid having any effect on the TGF ⁇ signalling pathway was not envisaged.
  • RAR receptors Two classes of nuclear receptors, RAR receptors and RXR receptors, are involved in the transcriptional response to retinoic acid (RA) .
  • RA retinoic acid
  • RARs retinoic acid receptors
  • RXRs retinoid X receptors
  • RARs associated with RXRs to form RAR-RXR heterodimers
  • RARs bind the target DNA sequence, namely the retinoic acid response elements (RARs), consisting of a direct repetition of the consensus sequence 5'-PuG(G/A) (T/A)CA-3' , separated by two or five nucleotides.
  • RARs retinoic acid response elements
  • the RAR family recognizes two natural stereoisomers of RA, all -trans-RA and 9-cis-RA, whereas the RXR family recognizes exclusively 5-cis-RA.
  • Retinoids are a family of compounds exhibiting a wide spectrum of therapeutic activities ranging from an anticancer activity to a skin-repairing activity (Altucci L and Gronemeyer H 2001 Nature Review 181-193, Sun SY and Lotan R (2002) Oncology Hematology 41: 41-55).
  • the present invention relates to the use of at least one RAR receptor antagonist, for preparing a pharmaceutical composition intended for the treatment of pathological conditions associated with a deficiency in the TGF ⁇ signal or requiring an amplification of this signal.
  • RAR receptor antagonist is intended to mean a synthetic or natural structural analogue of retinoic acid, capable of specifically binding and activating RAR receptors.
  • the RAR receptor antagonists according to the invention are compounds which are RAR ⁇ receptor antagonists.
  • the conventional techniques of the state of the art enable those skilled in the art to identify such RAR ⁇ receptor antagonists without particular difficulty, in particular using the mouse embryonic teratocarcinoma cell (F9) differentiation assay (Cancer Research 43, p. 5268, 1983) or the assay for ornithine decarboxylase inhibition after induction with TPA in mice (Cancer Research 38, p. 793-801, 1978) .
  • Synthetic antagonists will be preferred, preferably 4- (5, 5-dimethyl-8-p-tolyl- 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid.
  • potentiating agent is intended to mean a compound which potentiates the transcription induced by Smad factors via TGF ⁇ signalling.
  • composition used according to the present invention will be intended for the treatment of pathological conditions associated with a disorder of the transcription induced by Smad factors via TGF ⁇ signalling.
  • pathological conditions associated with a deficiency in the TGF ⁇ signal or requiring an amplification of this signal is intended to mean: wound-healing disorders, such as ulcers, in particular venous ulcers, diabetic ulcers and pressure sores; the improvement of normal wound healing, such as post-operative wound healing, in particular in the acceleration of wound healing (Bernstein E, Harisiadis L, Salomon G et al., Transforming Growth
  • the use according to the present invention is suitable for the treatment of pathological conditions associated with collagen type VII (COL7A1) .
  • the present invention relates to pharmaceutical compositions comprising at least one RAR receptor antagonist, intended for treatments for pathological conditions associated with a deficiency in the TGF ⁇ signal or requiring an amplification of this signal .
  • RAR receptor antagonists intended for treatments for pathological conditions associated with a deficiency in the TGF ⁇ signal or requiring an amplification of this signal .
  • Example 1 Measurement of the potentiation of the action of RARs on the transactivation of an Smad3-dependent promoter by RAR antagonists
  • a first approach for examining the potentiation of RAR signalling and of that of TGF ⁇ /Smad is to determine the effect of the various RAR agonists and antagonists on TGF ⁇ -induced, Smad-dependent transactivation of the luciferase reporter gene (lux) in WI-26 lung fibroblasts transfected with the construct (CAGA)g-lux.
  • lux luciferase reporter gene
  • the latter is made up of nine copies of the CAGA nucleotide motif, known to bind Smad3 and Smad4 with high affinity, cloned upstream of the adenoviral major late promoter (MLP) controlling expression of the lux reporter gene.
  • MLP adenoviral major late promoter
  • Example 2 Demonstration of the dose-dependent potentiating effect of the RAR antagonists on the TGF ⁇ -induced, Smad-specific transcriptional response
  • a culture of WI-26 fibroblasts, at confluency, is transfected with the (CAGA)g-lux gene. After a glycerol shock, DMEM containing 1% of FCS (foetal calf serum) is added. Three hours later, increasing concentrations of the synthetic RAR antagonist, 4- (5, 5-dimethyl-8-p-tolyl-
  • Cos-7 cells are transfected with the expression vectors for Smad3 labelled with Flag and Gal4BD-RAR ⁇ -D-E-F, in the presence or absence (see Figure 3, lanes 1-3) of either 4- [ (5, 5, 8, 8-tetramethyl- 5,6,7, 8-tetrahydronaphthalen-2-ylamino)methyl] benzoic acid (lanes 4-6), or 4- (5, 5-dimethyl-8-p-tolyl- 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid (lanes 7-9) .
  • Gal4-e The empty Gal 4 expression vector (Gal4-e) is used as a control.
  • 2-ylethynyl) benzoic acid are added. Forty hours later, the cell lysate is immunoprecipitated with anti-Gal4 antibodies and the co-precipitation of Smad3 is detected by immunoblotting with anti-FlaG antibodies (labelling of Smad) (top panel) . The expression of RAR ⁇ and Smad3 is confirmed by Western blotting using anti-Flag (middle panel) and anti-Gal4 (bottom panel) antibodies .
  • the migration bands in lanes 2, 5 and 8, obtained with the anti-Gal4 antibody correspond to the Gal4BD protein not fused to RAR ⁇ , expressed by the empty Gal4BD vector.
  • the effect of the RAR antagonists on COL7A1 promoters is quantified via the transactivation of the luciferase reporter gene (lux) .
  • Figure 5 represents a Northern blotting gel on which it is observed, without any transfection, that the response of endogenous C0L7A1 to TGF ⁇ is potentiated by the RAR antagonist. This assay also makes it possible to confirm all the transfection experiments described above.
  • 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid are the genes involved in particular pathological conditions, involving the promoter for collagen type VII (COL7A1) , such as: certain genetic pathological conditions, for instance epidermolysis bullosa, and some cases of wound healing which can be improved by stimulating the synthesis of collagen type VII, promoting epithelialization.
  • pathological conditions involving the promoter for collagen type VII (COL7A1) , such as: certain genetic pathological conditions, for instance epidermolysis bullosa, and some cases of wound healing which can be improved by stimulating the synthesis of collagen type VII, promoting epithelialization.
  • the potentiation of its activity with these antagonists may prevent or treat such pathological conditions.

Abstract

The present invention relates to the use of at least one RAR receptor antagonist as an agent which potentiates the action of TGFβ, for preparing a pharmaceutical composition intended for the treatment or prevention of pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal.

Description

USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING
THE ACTION OF TGFβ
The present invention relates to the use of at least one agent which potentiates the action of TGFβ, for preparing a pharmaceutical composition intended for the treatment or prevention of pathological conditions associated with a deficiency in the TGFβ signal" or requiring an amplification of this signal . TGFβ (Transforming Growth Factor-β) is a cytokine which plays an important role in regulating cell growth and differentiation. Smad proteins translate the signal from TGFβ receptors by regulating the transcription of target genes, either directly or in combination with other specific sequence transcription factors.
The intracellular signalling cascade for members of the TGFβ superfamily is initiated by binding of the cytokine to a complex of membrane receptors made up of two types of receptor with serine/threonine kinase activity, type I receptors and type II receptors. Binding of the cytokine to the type II receptor induces recruitment and phosphorylation of the type I receptor. Translation of the signal from the membrane to the nucleus then takes place by virtue of a family of proteins, the S ads . The Smad family can be divided up into three subfamilies according to structural and functional criteria. R-Smads (Receptor- regulated Smads), which are specifically activated by the type I receptors, comprise Smadl, Smad5 and Smad8 which are specific for the BMP pathway, and Smad2 and Smad3 which are specific for the TGFβ/activin pathway. Phosphorylation of the R-Smads by the type I receptors takes place on serine residues located at the C-terminal end of the protein (SSXS motif) . Activation of these R-Smads allows the formation of a heterocomplex with another member of the Smad family, common to the various R-Smads, Smad . This protein, also referred to as co-Smad (common-partner Smad) , lacks the SSXS sequence and allows the translocation into the nucleus of the R-Smad/Smad4 complex, which can then act as a transcription factor. The third subfamily consists of Smadβ and Smad7, referred to as I-Smads ( Inhibitory-Smads) , which prevent the phosphorylation of R-Smads and thus their association with Smad4 and/or the translocation of the R-Smad/Smad4 complex into the nucleus by interacting directly with Smad4.
TGFβ is also involved in other signalling pathways, such as that of MAP/SAP kinase or else the Ras pathway.
At the current time a series of TGFβ-related pathological conditions exist for which therapeutic solutions are necessary.
Specifically, TGFβ is a key cytokine in the control of connective tissue homeostasis and plays a major role in the profibrotic activity by increasing the expression of connective tissue-specific genes (Mauviel A and Uitto J. (1993) Wounds 5: 137-52). In addition, TGFβ plays an important role in immunomodulation processes, by acting on lymphocyte differentiation (Kehrl et al, 1986, J Immunol, 137, 3855-3860, Gorelik and Flavell, 2002, Nature, 2, 46-53). The Applicant has noted, surprisingly, that the use of an RAR receptor antagonist results in potentiation of the action of TGFβ. Thus, the present invention proposes a solution for treating pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal.
This use is in no way evident in view of the prior art since said prior art does not enable those skilled in the art to identify any advantage in using RAR receptor antagonists in the treatment of pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal .
In fact, the prior art describes that retinoids and TGFβ follow complex signalling pathways, which are all the more complex since they differ according to the subtype of receptor activated; by way of example, for retinoids, the signalling pathway depends on the RAR and RXR receptors and on the subtype involved (α, β or γ) . Finally, it should be noted that these signalling pathways are independent. Thus, the possibility of a retinoid having any effect on the TGFβ signalling pathway was not envisaged.
Two classes of nuclear receptors, RAR receptors and RXR receptors, are involved in the transcriptional response to retinoic acid (RA) .
The classes of retinoic acid receptors (RARs) and of retinoid X receptors (RXRs) are respectively subdivided into α, β and γ subtypes, with more than one isoform for each subtype (Chambon, 1996) . RARs, associated with RXRs to form RAR-RXR heterodimers, bind the target DNA sequence, namely the retinoic acid response elements (RARs), consisting of a direct repetition of the consensus sequence 5'-PuG(G/A) (T/A)CA-3' , separated by two or five nucleotides. The RAR family recognizes two natural stereoisomers of RA, all -trans-RA and 9-cis-RA, whereas the RXR family recognizes exclusively 5-cis-RA.
Retinoids are a family of compounds exhibiting a wide spectrum of therapeutic activities ranging from an anticancer activity to a skin-repairing activity (Altucci L and Gronemeyer H 2001 Nature Review 181-193, Sun SY and Lotan R (2002) Oncology Hematology 41: 41-55).
Thus, the present invention relates to the use of at least one RAR receptor antagonist, for preparing a pharmaceutical composition intended for the treatment of pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal.
The expression "RAR receptor antagonist" is intended to mean a synthetic or natural structural analogue of retinoic acid, capable of specifically binding and activating RAR receptors. Preferably, the RAR receptor antagonists according to the invention are compounds which are RARγ receptor antagonists. The conventional techniques of the state of the art enable those skilled in the art to identify such RARγ receptor antagonists without particular difficulty, in particular using the mouse embryonic teratocarcinoma cell (F9) differentiation assay (Cancer Research 43, p. 5268, 1983) or the assay for ornithine decarboxylase inhibition after induction with TPA in mice (Cancer Research 38, p. 793-801, 1978) .
Synthetic antagonists will be preferred, preferably 4- (5, 5-dimethyl-8-p-tolyl- 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid.
The term "potentiating agent" is intended to mean a compound which potentiates the transcription induced by Smad factors via TGFβ signalling.
Thus, the composition used according to the present invention will be intended for the treatment of pathological conditions associated with a disorder of the transcription induced by Smad factors via TGFβ signalling. The expression "pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal" is intended to mean: wound-healing disorders, such as ulcers, in particular venous ulcers, diabetic ulcers and pressure sores; the improvement of normal wound healing, such as post-operative wound healing, in particular in the acceleration of wound healing (Bernstein E, Harisiadis L, Salomon G et al., Transforming Growth
Factor-b improves healing of radiation-impaired wounds. J Invest Dermatol 1991; 97: 430-434; Mauviel A and Uitto J. The extracellular Matrix in Wound Healing: Role of the cytokine Network. Wounds 1993; 5(3): 137-152); some cancers, in particular those associated with a loss of control of TGFβ on cell proliferation (Engle SJ et al., 1999 Transforming growth factor betal suppresses nonmetasta ti c colon cancer a t an early stage of tumor igenes is - Cancer Res . 59, 3379-3386; Tang B et al., 1998); transplant rejection, in particular by promoting immune tolerance (Eikmans M et al . , 2002 High transforming growth factor-beta and extracellular ma trix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection - Transplan ta tion . 73, 4, 573-579); pathological conditions involving collagen type VII (COL7A1), in particular genetic pathological conditions in which a single allele is affected, such as epidermolysis bullosa or certain cases of wound healing which can be improved by stimulating the synthesis of collagen type VII, promoting epithelialization (Christiano AM, Greenspan DS, Hoffman GG, Zhang X, Tamai Y, Lin AN, Dietz HC, Hovnanian A, Uitto J. A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet. 1993 May; 4(1): 62-6.
In particular, the use according to the present invention is suitable for the treatment of pathological conditions associated with collagen type VII (COL7A1) .
Finally, the present invention relates to pharmaceutical compositions comprising at least one RAR receptor antagonist, intended for treatments for pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal . EXAMPLES Example 1 : Measurement of the potentiation of the action of RARs on the transactivation of an Smad3-dependent promoter by RAR antagonists A first approach for examining the potentiation of RAR signalling and of that of TGFβ/Smad is to determine the effect of the various RAR agonists and antagonists on TGFβ-induced, Smad-dependent transactivation of the luciferase reporter gene (lux) in WI-26 lung fibroblasts transfected with the construct (CAGA)g-lux. The latter is made up of nine copies of the CAGA nucleotide motif, known to bind Smad3 and Smad4 with high affinity, cloned upstream of the adenoviral major late promoter (MLP) controlling expression of the lux reporter gene.
A culture of WI-26 fibroblasts, at confluency, was co-transfected with (CAGA)g-lux and an expression vector encoding RARγ, in the absence (-) or in the presence (+) of the expression vector expressing Smad3. Three hours after transfection, four compounds are added:
- the RAR antagonist: 4- (5, 5-dimethyl-8-p-tolyl-
5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid at 10"6 M (1 μl of a 10"3 M solution in DMSO introduced into 1 ml of 1% medium) ;
- the RAR agonist: 4- [ (5, 5, 8 , 8-tetramethyl-
5, 6, 7, 8-tetrahydronaphthalen-2-ylamino) methyl] benzoic acid at 10~7 M (1 μl of a 10~4 M solution introduced in DMSO into 1 ml of 1% medium) ;
- ATRA (all-trans-retinoic acid) at 10"7 M (1 μl of a 10"4 M solution introduced in DMSO into 1 ml of 1% medium) ;
- control (Ctrl) : 1 μl of DMSO.
The luciferase activity is determined 24 hours later. The role of the synthetic RAR agonists and antagonists on the functional interactions between Smad3 and RARγ was examined, and the results are given in Figure 1. 4- (5, 5-Dimethyl-8-p-tolyl-5, 6-dihydro- naphthalen-2-ylethynyl) enzoic acid (RAR antagonist) potentiates the effect of RARγ on Smad3-dependent transcription, whereas 4- [ (5, 5, 8, 8-tetramethyl- 5, 6, 7, 8-tetrahydronaphthalen-2-ylamino) methyl] benzoic acid (RAR agonist) abolishes the effect of RARγ. Example 2 : Demonstration of the dose-dependent potentiating effect of the RAR antagonists on the TGFβ-induced, Smad-specific transcriptional response A culture of WI-26 fibroblasts, at confluency, is transfected with the (CAGA)g-lux gene. After a glycerol shock, DMEM containing 1% of FCS (foetal calf serum) is added. Three hours later, increasing concentrations of the synthetic RAR antagonist, 4- (5, 5-dimethyl-8-p-tolyl-
5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid, are added. These results (represented in Figure 2) show that the antagonist, 4- (5, 5-dimethyl-8-p-tolyl- 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid, potentiates in a dose-dependent manner the TGFβ-induced, Smad-dependent transcriptional response, with a maximum effect (+190%) at the concentration of 10"6 M. At a concentration of 10~8 M, the 4- (5, 5-dimethyl-8-p-tolyl-5, 6-dihydronaphthalen- 2-ylethynyl) benzoic acid doubles the extent of the TGFβ-dependent response.
Example 3 : Molecular demonstration of the RAR antagonists/Smad interaction via immunoprecipitation (IP) and immunoblotting experiments
Cos-7 cells are transfected with the expression vectors for Smad3 labelled with Flag and Gal4BD-RARγ-D-E-F, in the presence or absence (see Figure 3, lanes 1-3) of either 4- [ (5, 5, 8, 8-tetramethyl- 5,6,7, 8-tetrahydronaphthalen-2-ylamino)methyl] benzoic acid (lanes 4-6), or 4- (5, 5-dimethyl-8-p-tolyl- 5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid (lanes 7-9) .
The empty Gal 4 expression vector (Gal4-e) is used as a control.
Three hours after transfection, 10"6 M of 4- (5, 5-dimethyl-8-p-tolyl-5, 6-dihydronaphthalen-
2-ylethynyl) benzoic acid, are added. Forty hours later, the cell lysate is immunoprecipitated with anti-Gal4 antibodies and the co-precipitation of Smad3 is detected by immunoblotting with anti-FlaG antibodies (labelling of Smad) (top panel) . The expression of RARγ and Smad3 is confirmed by Western blotting using anti-Flag (middle panel) and anti-Gal4 (bottom panel) antibodies .
The migration bands in lanes 2, 5 and 8, obtained with the anti-Gal4 antibody correspond to the Gal4BD protein not fused to RARγ, expressed by the empty Gal4BD vector.
After immunoprecipitation with an anti-Gal4BD antibody (top panel) , Western blotting with anti-Flag antibodies reveals the co-immunoprecipitation of Smad3 with RARγ in lane 3. The amount of RARγ binding Smad3 is significantly increased by the presence of 4- (5, 5-dimethyl-8-p-tolyl-5, 6-dihydronaphthalen- 2-ylethynyl) benzoic acid, lane 9. This indicates that the potentiation by the RAR antagonist, 4- (5, 5-dimethyl-8-p-tolyl-5, 6-dihydronaphthalen-
2-ylethynyl) benzoic acid, of the action of TGFβ, i.e. the increase in the transcriptional response induced by TGFβ, involves an increase in the amount of Smad3-RARγ heterocomplex formed. Example 4 : Effects of the RAR antagonists on the TGFβ-induced activity of the promoter for collagen type VII (COL7A1)
The effect of the RAR antagonists on COL7A1 promoters (collagen type VII promoter) is quantified via the transactivation of the luciferase reporter gene (lux) .
In the presence of the RAR antagonist, 4- (5, 5-dimethyl-8-p-tolyl-5, 6-dihydronaphthalen- 2-ylethynyl) benzoic acid, and of TGFβ, a dose-dependent increase in the TGFβ-induced transcription of the reporter gene under the control of the promoter for collagen type VII (COL7A1) is observed (Figure 4). Example 5 : Effect of the RAR antagonists and agonists on the modulation of the response of endogenous COL7A1 to TGFβ
Furthermore, Figure 5 represents a Northern blotting gel on which it is observed, without any transfection, that the response of endogenous C0L7A1 to TGFβ is potentiated by the RAR antagonist. This assay also makes it possible to confirm all the transfection experiments described above.
This assay was carried out according to the following protocol: confluent HaCaT cultures were treated with the agonist, 4- [ (5, 5, 8 , 8-tetramethyl-
5,6,7, 8-tetrahydronaphthalen-2-ylamino) methyl] benzoic acid, at 10"7 M, and the antagonist, 4- (5, 5-dimethyl- 8-p-tolyl-5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid, at 10~6 M, as described in Example 1, in the presence or absence of TGFβ (at 10 ng/ml) for 48 hours. After extraction of the total RNA, the collagen type VII mRNA level was quantified by Northern blotting using a 32P-labelled specific cDNA probe. A probe characteristic of the mRNA of the GADPDH protein was used as a control for loading.
The genes which are targets for the action of the antagonist, 4- (5, 5-dimethyl-8-p-tolyl-
5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid, are the genes involved in particular pathological conditions, involving the promoter for collagen type VII (COL7A1) , such as: certain genetic pathological conditions, for instance epidermolysis bullosa, and some cases of wound healing which can be improved by stimulating the synthesis of collagen type VII, promoting epithelialization.
Thus, the potentiation of its activity with these antagonists may prevent or treat such pathological conditions.

Claims

1. Use of at least one RAR receptor antagonist, for preparing a pharmaceutical composition intended for the treatment of pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal.
3. Use according to Claim 1, characterized in that the RAR receptor antagonist is 4- (5, 5-dimethyl- 8-p-tolyl-5, 6-dihydronaphthalen-2-ylethynyl) benzoic acid.
3. Use according to Claim 1 or 2, characterized in that the composition is intended for the treatment of pathological conditions associated with a disorder of the transcription induced by Smad factors via TGFβ signalling.
4. Use according to Claim 1 or 2, characterized in that the composition is intended for the treatment: of wound-healing disorders, such as ulcers, in particular venous ulcers, diabetic ulcers and pressure sores; of physiological situations such as post-operative wound healing, in particular in the acceleration of wound healing; - of cancers associated with a loss of control of TGFβ on cell proliferation; of transplant rejection, in particular by promoting immune tolerance; of pathological conditions involving collagen type VII (COL7A1), in particular of "certain genetic pathological conditions such as epidermolysis bullosa, or of certain cases of wound healing which can be improved by stimulating the synthesis of collagen type VII, promoting epithelialization.
5. Use according to Claim 1 or 2, for preparing a pharmaceutical composition intended for the treatment of pathological conditions associated with collagen type VII (COL7A1) .
6. Pharmaceutical composition comprising at least one RAR receptor antagonist, intended for treatments for pathological conditions associated with a deficiency in the TGFβ signal or requiring an amplification of this signal.
PCT/EP2003/014864 2002-11-15 2003-11-14 USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ WO2004045595A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003302070A AU2003302070A1 (en) 2002-11-15 2003-11-14 USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFBeta

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0214319A FR2847167A1 (en) 2002-11-15 2002-11-15 Method for treating disorders associated with TGF-beta signal deficiency, e.g. cicatrization disorders, ulcers, cancers or graft rejection, comprises administration of retinoic acid receptor-Gamma antagonists
FR02/14319 2002-11-15
US43067102P 2002-12-04 2002-12-04
US60/430,671 2002-12-04

Publications (1)

Publication Number Publication Date
WO2004045595A1 true WO2004045595A1 (en) 2004-06-03

Family

ID=32327936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/014864 WO2004045595A1 (en) 2002-11-15 2003-11-14 USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ

Country Status (2)

Country Link
AU (1) AU2003302070A1 (en)
WO (1) WO2004045595A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020930A1 (en) * 1994-12-29 1996-07-11 Allergan Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
WO1998011886A1 (en) * 1996-09-20 1998-03-26 Centre International De Recherches Dermatologiquesgalderma (C.I.R.D. Galderma) Use of inhibitors of retinoic acid activity for wound healing
WO1998046223A1 (en) * 1997-04-11 1998-10-22 Bristol-Myers Squibb Company Retinoid antagonists for prevention of surgical adhesions
US6248749B1 (en) * 1996-10-31 2001-06-19 Centre International De Recherches Dermatologiques Galderma Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation
WO2001043732A2 (en) * 1999-12-15 2001-06-21 Allergan, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020930A1 (en) * 1994-12-29 1996-07-11 Allergan Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
WO1998011886A1 (en) * 1996-09-20 1998-03-26 Centre International De Recherches Dermatologiquesgalderma (C.I.R.D. Galderma) Use of inhibitors of retinoic acid activity for wound healing
US6248749B1 (en) * 1996-10-31 2001-06-19 Centre International De Recherches Dermatologiques Galderma Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation
WO1998046223A1 (en) * 1997-04-11 1998-10-22 Bristol-Myers Squibb Company Retinoid antagonists for prevention of surgical adhesions
WO2001043732A2 (en) * 1999-12-15 2001-06-21 Allergan, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHARON O'KANE ET ALL.: "Transforming Growth Factor betas and Wound Healing", INT. J. BIOCHEM.CELL BIOL., vol. 29, 1997, pages 63 - 78, XP008018620 *
SHI-YONG SUN ET ALL.: "Identification of Receptor-selective Retinoids That are Potent Inhibitors of the Growth of Human Head and Neck Squamous Cell Carcinoma Cells", CLINICAL CANCER RESEARCH, vol. 6, April 2000 (2000-04-01), pages 1563 - 1573, XP002244961 *

Also Published As

Publication number Publication date
AU2003302070A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
Viñals et al. Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling
Verrecchia et al. Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation
McCarthy et al. Novel links among Wnt and TGF-β signaling and Runx2
Riser et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease
Nagai et al. Significance of the transcription factor KLF5 in cardiovascular remodeling
Shah et al. A review of platelet derived growth factor playing pivotal role in bone regeneration
Sulyok et al. Activin: an important regulator of wound repair, fibrosis, and neuroprotection
Liu et al. Wnt/β-catenin pathway forms a negative feedback loop during TGF-β1 induced human normal skin fibroblast-to-myofibroblast transition
Quan et al. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin
Hayashida et al. TGF-β1 activates MAP kinase in human mesangial cells: a possible role in collagen expression
Wang et al. Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes
Lewis et al. Bone morphogenetic protein signaling suppresses wound-induced skin repair by inhibiting keratinocyte proliferation and migration
Walraven et al. Altered TGF‐β signaling in fetal fibroblasts: What is known about the underlying mechanisms?
Folger et al. Transforming Growth Factor-β–Stimulated Connective Tissue Growth Factor Expression during Corneal Myofibroblast Differentiation
Kim et al. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II
Zunwen et al. Effect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro
Santibanez et al. Caveolin-1 interacts and cooperates with the transforming growth factor-β type I receptor ALK1 in endothelial caveolae
Kahler et al. Lymphocyte enhancer‐binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts
Dupuy et al. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1α
Niu et al. Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin β4
Zhang et al. Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars
Zhao et al. Transdermal siRNA-TGFβ1-337 patch for hypertrophic scar treatment
Wagner et al. Therapeutic implications of PPAR in human osteosarcoma
Suzuki et al. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts
Van Roeyen et al. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP